Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cancer Chemotherapy Regimen for Colon Cancer


 MOF-S                                                   colon(49)
 _________________________________________________________________
  semustine....... 30 mg/sqm/day orally on days 1 to 5 inclusive.
  vincristine..... 1 mg IV day 1 and day 35 (5 weeks).
  fluorouracil.... 300 mg/sqm/day IV on days 1 to 5 and on days 35 
                   to 40, inclusive.
  streptozotocin.. 500 mg/sqm IV on day 1 and weekly thereafter.
  FREQUENCY....... Repeat cycle every 70 days (10 weeks).

  reference...
    Kemeny N.  Yagoda A.  Braun D Jr.  Golbey R. Therapy for 
    metastatic colorectal carcinoma with a combination of 
    methyl-CCNU, 5-fluorouracil vincristine and streptozotocin 
    (MOF-Strep). Cancer.  45(5):876-81, 1980 Mar 1. 
  abstract...
    Seventy-seven previously untreated patients with measurable 
    metastatic colorectal carcinoma were treated with a 
    combination of methyl-CCNU, 5-fluorouracil (5-FU), vincristine 
    and streptozotocin (MOF-Strep). The treatment schedule 
    consisted of methyl-CCNU, 30 mg/m2 for 5 consecutive days q 10 
    weeks; 5-FU, 300 mg/m2 IV for five consecutive days q 5 weeks; 
    vincristine, 1 mg IV q 5 weeks; and streptozotocin, 500 mg/m2 
    IV weekly. Two (3%) patients achieved complete remission (CR); 
    22 (29%) patients, a partial remission (PR); and 13 (18%) 
    patients, a minor remission (MR). The median duration of 
    remission was eight months (range, 4-25+months) for patients 
    obtaining CR/PR status, and six months (range, 4-15 months) 
    for MR status. The median survival time was 14 months for 
    patients achieving CR/PR versus seven months for non 
    responders. Comparison with a previous study of MOF at 
    Memorial Sloan-Kettering Cancer Center, showed that the 
    MOF-Strep combination produced a significant (P = 0.004) 
    increase in the number of complete and partial remissions, 32% 
    versus 11%, and in survival, 11 versus 9 months, (P = 0.003), 
    respectively. 
 
advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.